Kymriah® is indicated for the treatment of paediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse, and adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.1
Global manufacturing network to meet the needs of patients worldwide
*Novartis is committed to ensuring slot availability and minimised treatment delay for as many patients as possible.
- Kymriah Summary of Product Characteristics; April 2020.
- Data on file. Kymriah. Novartis Pharmaceuticals Corp; October 2020.
- Pharmatech. Novartis Gets EMA Approval for Two European Commercial CAR-T Manufacturing Sites. Available at: https://www.pharmtech.com/view/novartis-gets-ema-approval-for-two-europe... [Accessed December 2021].